Translational Genomics Research Institute (TGen)
The Translational Genomics Research Institute (TGen), a nonprofit organization, is focused on developing earlier diagnoses and smarter treatments. Translational genomics research employs innovative advances arising from the Human Genome Project by applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, infectious disease, metabolic and other complex diseases. TGen's research is based on personalized medicine, and the institute plans to accomplish its goals through robust and disease-focused research.
TGen partners with others in academic and scientific communities in Arizona and beyond to improve the efficiency and effectiveness of the translational research process. Recent highlights include work related to brain tumors, pancreatic cancer, H1N1 (swine flu), DNA identification (forensics) and clinical trials for various types of cancer.
"The foundation for successful biomedical research organizations rests on the ability to attract and retain scientific talent around a core mission," said Tess Burleson, chief operating officer.
While National Institutes of Health funding is key, many new scientists are not able to immediately secure such funding. Other funding sources, such as TGen, are critical to provide first awards scientists need to eventually obtain NIH funding.
"Quite simply, without the various sources of funding, research could not happen," Burleson said. "No money, no mission."
This month, TGen and the Van Andel Research Institute in Grand Rapids, MI, will finalize a strategic alliance enabling both institutes to maximize their worldwide contributions to science and health and accelerate their mutual goal of quickly moving research discoveries from laboratories to patient care.
To learn more, visit www.tgen.org.
Read past member spotlights from The Research Advocate.
Tags: member spotlight, Tess Burleson, TGen